Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775461 · ClinicalTrials.gov registry record
Pancreas Registry and High Risk Registry
A clinical trial of Pancreas Cancer and Chronic Pancreatitis, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 1,368
- Enrollment target
- 2
- Study locations
NCT02775461: Recruiting study of Pancreas Cancer and Chronic Pancreatitis, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02775461 is a study of Pancreas Cancer and Chronic Pancreatitis that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 1,368 participants, above the 882-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (55% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02775461, a study of Pancreas Cancer and Chronic Pancreatitis, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 1,368 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-risk of pancreatic cancer such as those with a family history of pancreatic cancer or with a family history of a syndrome known to be associated with pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the United States. However, little is known about the development of pancreatic cancer and pancreatic diseases in individuals with the above conditions. Knowledge of how family history, environmental exposures, and inflammatory lesion of the pancreas contribute to the development of pancreatic cancer and pancreatic diseases is essential. You may qualify to take part in this research study because you have inflammation in the pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a family history of pancreatic cancer, or a family history of a syndrome known to be associated with pancreatic cancer. We will also be collecting a blood sample from all participants for DNA isolation. Sometimes we are born with genes or DNA that give us an increased or decreased chance of developing an illness later in life. Genetic material will be isolated from your blood for further study. You may also choose to provide additional blood samples for serum and plasma extraction. Serum and plasma are components of the blood which can be used to measure indicators of disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer. Funds for conducting this research are provided by Mount Sinai.
Primary Outcome
Number of individuals and their family members who have pancreatic diseases and may be at increased risk of developing pancreatic cancer over normal population risk.
Conditions Studied
Study Locations (2)
New York
- Mount Sinai West - New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,368 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2033-01 |
What NCT02775461 shows while recruiting
NCT02775461 is an observational study that tracks outcomes without assigning an intervention. Its 1,368 participants enrollment target places it among the larger protocols in the corpus, above the 882-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (55% higher).
The record links to 6 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02775461 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02775461 about?
NCT02775461 is a clinical study titled "Pancreas Registry and High Risk Registry". The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-ris...
What is the current status of trial NCT02775461?
This trial is currently recruiting. The enrollment target is 1,368 participants. The study started on 2013-03-01. Estimated completion is 2033-01.
What conditions does trial NCT02775461 study?
This clinical trial studies the following conditions: Pancreas Cancer, Chronic Pancreatitis, Pancreatic Cyst, Pancreatitis, Genetic Mutations.
Who is sponsoring clinical trial NCT02775461?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02775461 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02775461's enrollment target sits among peer trials
1,368 6th of 54 higher than 49 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI